Updated BSR Guideline is published for csDMARDs

"The updated guideline, endorsed by Royal Pharmaceutical Society (RPS), includes the whole life course, providing guidance for the care of children and young people for the first time." 

Juvenile Arthritis Research has welcomed this important guideline update from the British Society for Rheumatology. The guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) has just been published. 

With input from a multi-disciplinary team (MDT), the Guideline Working Group (GWG) included paediatric rheumatologists, paediatric pharmacists, and specialist nurses to ensure that the guideline would meet the needs of those caring for children and young people with rheumatic conditions including Juvenile Idiopathic Arthritis (JIA). 

In many cases, csDMARDs including drugs such as methotrexate, are the first line of treatment for those with JIA so it is crucial that those caring for children and young people with JIA have these evidence-based guidelines to use when making treatment decisions. 

Juvenile Arthritis Research has been involved in this project to ensure that the patient voice is represented through the guideline review process. 

Read more in the British Society for Rheumatology's news piece here. The full published guideline is available in the BSR's Rheumatology Journal here. And an infographic version of the guide can be found here.